MedPath

Hillhurst Biopharmaceuticals, Inc.

Hillhurst Biopharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2012-01-01
Employees
1
Market Cap
-
Website
http://www.hillhurstbio.com

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Phase 2
Not yet recruiting
Conditions
Parkinson Disease
Interventions
Drug: Vehicle (placebo)
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
Hillhurst Biopharmaceuticals, Inc.
Target Recruit Count
36
Registration Number
NCT07005180

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Phase 1
Recruiting
Conditions
Anemia, Sickle Cell
Interventions
First Posted Date
2023-11-22
Last Posted Date
2025-05-29
Lead Sponsor
Hillhurst Biopharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT06144749
Locations
🇵🇦

Cevaxin - The Panama Clinic, Panama City, Panama

🇵🇦

Hospital Pacífica Salud, Panama City, Panama

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Phase 1
Completed
Conditions
Anemia, Sickle Cell
Interventions
First Posted Date
2019-04-25
Last Posted Date
2025-05-23
Lead Sponsor
Hillhurst Biopharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT03926819
Locations
🇺🇸

Contact Company, San Diego, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.